Legend Biotech Statistics
Total Valuation
Legend Biotech has a market cap or net worth of $6.82 billion. The enterprise value is $6.24 billion.
Important Dates
The last earnings date was Monday, August 11, 2025, before market open.
| Earnings Date | Aug 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Legend Biotech has 184.57 million shares outstanding. The number of shares has increased by 0.90% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 184.57M |
| Shares Change (YoY) | +0.90% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 0.14% |
| Owned by Institutions (%) | 63.74% |
| Float | 81.38M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 158.50 |
| PS Ratio | 8.51 |
| Forward PS | n/a |
| PB Ratio | 6.58 |
| P/TBV Ratio | 6.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.83 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.71, with a Debt / Equity ratio of 0.37.
| Current Ratio | 4.71 |
| Quick Ratio | 4.51 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10.40 |
Financial Efficiency
Return on equity (ROE) is -29.65% and return on invested capital (ROIC) is -9.32%.
| Return on Equity (ROE) | -29.65% |
| Return on Assets (ROA) | -7.81% |
| Return on Invested Capital (ROIC) | -9.32% |
| Return on Capital Employed (ROCE) | -15.29% |
| Revenue Per Employee | $305,419 |
| Profits Per Employee | -$124,696 |
| Employee Count | 2,609 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 25.67 |
Taxes
In the past 12 months, Legend Biotech has paid $21.03 million in taxes.
| Income Tax | 21.03M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.35% in the last 52 weeks. The beta is 0.26, so Legend Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.26 |
| 52-Week Price Change | -34.35% |
| 50-Day Moving Average | 37.47 |
| 200-Day Moving Average | 36.17 |
| Relative Strength Index (RSI) | 41.02 |
| Average Volume (20 Days) | 1,276,484 |
Short Selling Information
| Short Interest | 7.82M |
| Short Previous Month | 8.39M |
| Short % of Shares Out | 8.15% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 5.53 |
Income Statement
In the last 12 months, Legend Biotech had revenue of $796.84 million and -$325.33 million in losses. Loss per share was -$1.78.
| Revenue | 796.84M |
| Gross Profit | 97.93M |
| Operating Income | -217.84M |
| Pretax Income | -287.07M |
| Net Income | -325.33M |
| EBITDA | -209.01M |
| EBIT | -217.84M |
| Loss Per Share | -$1.78 |
Full Income StatementBalance Sheet
The company has $967.56 million in cash and $387.91 million in debt, giving a net cash position of $579.64 million or $3.14 per share.
| Cash & Cash Equivalents | 967.56M |
| Total Debt | 387.91M |
| Net Cash | 579.64M |
| Net Cash Per Share | $3.14 |
| Equity (Book Value) | 1.04B |
| Book Value Per Share | 5.61 |
| Working Capital | 984.39M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$274.70 million and capital expenditures -$15.67 million, giving a free cash flow of -$290.37 million.
| Operating Cash Flow | -274.70M |
| Capital Expenditures | -15.67M |
| Free Cash Flow | -290.37M |
| FCF Per Share | -$1.57 |
Full Cash Flow StatementMargins
Gross margin is 12.29%, with operating and profit margins of -27.34% and -40.83%.
| Gross Margin | 12.29% |
| Operating Margin | -27.34% |
| Pretax Margin | -38.19% |
| Profit Margin | -40.83% |
| EBITDA Margin | -26.23% |
| EBIT Margin | -27.34% |
| FCF Margin | n/a |
Dividends & Yields
Legend Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.90% |
| Shareholder Yield | -0.90% |
| Earnings Yield | -4.77% |
| FCF Yield | -4.26% |
Dividend DetailsAnalyst Forecast
The average price target for Legend Biotech is $73.67, which is 99.49% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $73.67 |
| Price Target Difference | 99.49% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 36.94% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Legend Biotech has an Altman Z-Score of 6.06 and a Piotroski F-Score of 3.
| Altman Z-Score | 6.06 |
| Piotroski F-Score | 3 |